Test Price
2,800 AED✅ Home Collection Available
CACNA1C Gene (Long QT Syndrome Type 8) Genetic Test in UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via Next-Generation Sequencing (NGS) processed under ISO 9001:2015 Certified Laboratory (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (available daily from 8 AM to 11 PM).
- Clinical Guidance: Complimentary telephonic post‑test counselling with a Consultant Medical Geneticist to interpret results and plan next steps.
- Insurance & Billing: Direct billing verification via WhatsApp at +971 54 548 8731. We handle prior approvals for major UAE networks.
Test Overview & Methodology
This genetic test employs advanced Next-Generation Sequencing to analyse the entire coding region of the CACNA1C gene, identifying pathogenic variants responsible for Long QT Syndrome Type 8 (Timothy syndrome). It provides definitive molecular confirmation and guides family cascade screening, reproductive planning, and personalised cardiac surveillance strategies.
| Feature | Our Test (NGS) | Closest Alternative (Single‑Gene Sequencing) |
|---|---|---|
| Precision | Full gene coverage + flanking intronic regions (99.9% sensitivity) | Targeted mutation hotspots only (~85% sensitivity) |
| Method | Illumina® Next-Generation Sequencing (NGS) with Sanger confirmation of all variants | Sanger sequencing of limited exons |
| Turnaround Time | 3‑4 weeks from receipt of sample | 6‑8 weeks |
*Based on internal validation against external proficiency testing samples.
Physician Insight & Safety Protocols
“This test can reveal important hereditary heart rhythm information, but I always stress that a CACNA1C variant must be interpreted in the context of a full cardiac work‑up, including ECG and clinical history. My team and I are here to help you integrate these results safely, never to replace ongoing cardiology care.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ Medication Advisory
Do not discontinue prescribed medication (e.g., beta‑blockers, anti‑arrhythmics) without consulting your doctor. Genetic test results alone do not determine treatment changes.
Exclusion Criteria & Emergency Red Flags
- Unable to provide informed consent (guardian consent mandatory for minors under Federal Decree‑Law No. 4 of 2016 on Medical Liability).
- Acute psychiatric crisis or cognitive inability to understand genetic implications.
- Known current adverse reaction to venipuncture that prevents blood draw (in such cases, FTA card collection may be arranged).
- If you experience sudden fainting, seizures, or sustained palpitations before or during the testing process, seek emergency medical attention immediately — this test is not a substitute for acute care.
Patient FAQ & Clinical Guidance
1. What exactly does the CACNA1C gene test detect?
This test detects DNA variants in the CACNA1C gene that cause Long QT syndrome type 8, a potentially life‑threatening heart rhythm disorder. The analysis covers all coding exons and adjacent intron boundaries using Next-Generation Sequencing, with all reported variants confirmed by Sanger sequencing. A positive result can trigger cascade screening in at‑risk relatives and guide implantation of cardioverter‑defibrillators when appropriate.
2. Who should consider undergoing this genetic test?
Individuals with a personal or family history of unexplained sudden cardiac arrest, syncope, or prolonged QT interval on ECG should strongly consider this test. It is also valuable for asymptomatic relatives of a confirmed Timothy syndrome patient, competitive athletes undergoing pre‑participation cardiac screening, and families planning pregnancy when one partner carries a known CACNA1C variant. All candidates must receive pre‑test genetic counselling in accordance with Federal Decree‑Law No. 4 of 2016 on Medical Liability.
3. How is the sample collected and what should I expect about turnaround time?
One blood sample or buccal swab is collected by a certified phlebotomist during a scheduled home visit, with a typical result delivery of 3 to 4 weeks. Whole blood, extracted DNA, or a single drop of blood on an FTA card are all acceptable specimens. The home collection service operates daily from 8 AM to 11 PM, and your sample is transported under cold‑chain conditions to our ISO‑certified laboratory. Once sequencing is complete, a detailed clinical report is issued and explained during your post‑ telephone consultation.
UAE Regulatory & Data Privacy Adherence
Data Protection: We fully comply with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access‑controlled, and processed solely for diagnostic and clinical counselling purposes.
Clinical & Logistical Metadata
| Test Name | CACNA1C Gene (Long QT Syndrome Type 8) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA), buccal swab, or FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | I45.81 (Long QT syndrome) |
| LOINC Code | 77991-4 (Genetic testing for Long QT syndrome) |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians